Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

Bibliographic Details
Title: Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Authors: Castro, Mario, Wenzel, Sally E, Bleecker, Eugene R, Pizzichini, Emilio, Kuna, Piotr, Busse, William W, Gossage, David L, Ward, Christine K, Wu, Yanping, Wang, Bing, Khatry, Deepak B, van der Merwe, René, Kolbeck, Roland, Molfino, Nestor A, Raible, Donald G
Source: In The Lancet Respiratory Medicine November 2014 2(11):879-890
Database: ScienceDirect
More Details
ISSN:22132600
DOI:10.1016/S2213-2600(14)70201-2
Published in:The Lancet Respiratory Medicine
Language:English